In the first-line setting, pembrolizumab monotherapy demonstrated improved progression-free survival (PFS) and overall survival (OS) benefit compared to chemotherapy in NSCLC patients with PD‐L1 expression on ≥ 50% of tumor cells (KEYNOTE 024) 9,11. Here, CD274 is linked to neoplasm.